Pediatric Diabetes Therapeutic Market To Reach $22.14 Billion By 2030

Pediatric Diabetes Therapeutic Market Growth & Trends

The global pediatric diabetes therapeutic market size is anticipated to reach USD 22.14 billion by 2030, growing at a CAGR of 13.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the rising prevalence of diabetes among children and the increasing focus on early diagnosis and effective management. The International Diabetes Federation (IDF) estimates that in 2022, out of the 8.75 million people living with type 1 diabetes (T1D) worldwide, only 1.52 million were under the age of 20. This surge is largely due to genetic predisposition, environmental factors, and changes in lifestyle patterns.

Technological advancements in diabetes management are anticipated to positively impact market growth. Innovations such as continuous glucose monitors (CGMs), insulin pumps, and artificial pancreas systems enable better glucose control, reducing the risk of complications. For example, in June 2023, the U.S. FDA approved Synjardy (a combination of metformin hydrochloride and empagliflozin) and Jardiance (empagliflozin) for use in children aged 10 and older with type 2 diabetic (T2D), as an adjunct to diet and exercise for better blood sugar control. This approval is expected to significantly enhance treatment options for pediatric with T2D, encouraging broader adoption of these medications in clinical practice. It marks a critical step in expanding access to effective therapies for younger patients, leading to improved disease management and better long-term health outcomes.

Furthermore, the growing awareness and early diagnosis of disease in children have led to an increase in the adoption of various treatment options, including insulin therapies, biguanides, GLP-1 receptor agonists, and SGLT2 inhibitors. The market is also driven by supportive government initiatives and policies aimed at improving access to diabetic care for children. As the global children population continues to rise, along with the increasing prevalence of diabetes, the demand for diabetic treatment is expected to grow significantly during the forecast period.

 Request a free sample copy or view report summary: Pediatric Diabetes Therapeutic Market Report

Pediatric Diabetes Therapeutic Market Report Highlights

• The type 1 segment held the largest revenue share of 79.32% in 2023. This can be attributed to the increasing incidence and prevalence of type 1 disease and high demand for new therapy treatment across worldwide.

• In treatment, the insulin segment is held the largest share of 35.88% of the market in 2023. This can be attributed to the development and commercialization of novel delivery systems to deliver insulin safely and effectively to children’s patients without harm.

• In route of administration, the parenteral segment is held the largest share of 62.50% of the market in 2023. This can be attributed to the growing approval of new subcutaneous and intravenous medicine for treatment of pediatric diabetes patient.

• In distribution channel, the retail pharmacies segment is held the largest share of 47.49% of the market in 2023. This can be attributed to its advantages such as easy accessibility and availability of medication to refill prescriptions of pediatric patients for diabetes treatment.

• North America dominated the market in 2023 with a share of 41.49%, owing to factors such as advanced healthcare infrastructure, increasing prevalence of diabetic in children, and favorable regulatory and reimbursement for clinical trial and treatment.

Pediatric Diabetes Therapeutic Market Segmentation

Grand View Research has segmented the global pediatric diabetes therapeutic market based on diabetes, treatment, route of administration, distribution channel, and region:

Pediatric Diabetes Therapeutic Type Outlook (Revenue, USD Million, 2018 - 2030)

• Type 1

• Type 2

Pediatric Diabetes Therapeutic Application Outlook (Revenue, USD Million, 2018 - 2030)

• Insulin

• GLP-1 Receptor Agonists

• Biguanide

• SGLT2 Inhibitors

• Others

Pediatric Diabetes Therapeutic Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Parenteral

• Others

Pediatric Diabetes Therapeutic Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Diagnostic Centers

• Online Pharmacies

Pediatric Diabetes Therapeutic Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • Kuwait

  • UAE

List of Key Players in the Pediatric Diabetes Therapeutic Market

• Boehringer Ingelheim International GmbH

• Eli Lilly and Company

• Sanofi

• Vertex Pharmaceuticals Incorporated

• Novo Nordisk A/S

• AstraZeneca

• MannKind Corporation

• Xeris Pharmaceuticals

• Amphastar Pharmaceuticals, Inc.